These studies have demonstrated that GSK3β inhibition can lead to reduced tau protein phosphorylation in models of Alzheimer’s disease, suggesting a potential therapeutic benefit in neurodegenerative contexts (Zhao et al., 2024). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.